NSE · MAITREYA · Healthcare
Maitreya Medicare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹47 Cr with net profit ₹2 Cr — a 3.96% net margin, versus 6.18% the period before.
Shareholding
As of 2026-03-31
- Promoter73.11%
- Public26.89%
976 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.57× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #39 of 79 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,29,191 Cr | 244.02 | 13.63 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,09,762 Cr | 74 | 10.22 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,672 Cr | 269.7 | 7.24 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,609 Cr | 50.82 | 9.39 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,273 Cr | 299.96 | 9.24 | 8.48% | 8.36% |
| Global Health Limited | ₹38,045 Cr | 263.99 | 9.6 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,953 Cr | 136.79 | 9.06 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,581 Cr | 239.68 | 12.59 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹16,985 Cr | 51.9 | 5.47 | 10.37% | 17.18% |
| Rainbow Childrens Medicare Ltd. | ₹15,471 Cr | 62.53 | 9.27 | 16.89% | 16.34% |
| Maitreya Medicare Limited(this company) | ₹80 Cr | 110.71 | 3.3 | -8.49% | 6.29% |
AI analysis
AI-generated · google/gemini-2.5-flashMaitreya Medicare Limited has a market capitalization of Rs 84 Cr. The company reported a revenue of Rs 47.23 Cr and a profit margin of 6.29%. The debt-to-equity ratio stands at 0.18. Promoter holding is 73.1117%.
Positives
- +The company's debt-to-equity ratio is low at 0.18, indicating limited reliance on borrowed capital.
- +Promoter holding of 73.1117% indicates a significant stake by the founders.
- +No promoter share pledges have been reported, suggesting financial stability among promoters.
Negatives
- −The company reported negative annual revenue growth of 2.3% for the most recent fiscal year.
- −Return on Equity (ROE) is -8.49%, indicating that the company is not generating positive returns for shareholders.
- −Return on Capital Employed (ROCE) is -1.8929%, suggesting inefficient use of overall capital.
- −The company reported negative net profit of Rs -1.07 Cr in March 2024 quarterly results and negative EBITDA of Rs -1.04 Cr.
- −The company's Price-to-Earnings (PE) ratio is high at 110.71, relative to its earnings performance.
Financial performance
Maitreya Medicare Limited's revenue decreased by 2.3% to Rs 47.23 Cr in the most recent fiscal year. Net profit for the same period was Rs 1.87 Cr. The company's earnings per share (EPS) for the last fiscal year was Rs 3.01. Quarterly revenue for March 2024 was Rs 12.32 Cr, reflecting a decrease from Rs 14.05 Cr in September 2023.
Profitability & returns
The company recorded a profit margin of 6.29% for the most recent fiscal year. However, the Return on Equity (ROE) was -8.49% and Return on Capital Employed (ROCE) was -1.8929%, indicating negative returns on shareholder funds and total capital employed. The Price-to-Earnings (PE) ratio is 110.71.
Balance sheet
Maitreya Medicare Limited has a book value per share of Rs 35.8. The company's debt-to-equity ratio is 0.18, indicating a relatively low level of debt compared to equity. No pledges have been reported against promoter shareholding.
Ownership & pledges
As of March 31, 2026, promoter holding in Maitreya Medicare Limited is 73.1117%. Public shareholding is 26.8883%. Foreign Institutional Investors (FII) holding was 0% as of March 31, 2026, a decrease from 0.4132% in September 2024. There are no reported promoter share pledges.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.